Who Owns Protalix BioTherapeutics (DE) Stock?
NYSE: PLXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 24.04%
- Held by insiders
- 3.72%
- Institutional holders
- 142
- Institutions 24.0%
- Insiders 3.7%
- Public and other 72.2%
Who owns Protalix BioTherapeutics (DE) stock?
Institutional investors own about 24.0% of Protalix BioTherapeutics (DE)'s shares, spread across 142 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 3.72% of PLX.
The largest institutional holders are Blackrock Inc. (4.80%), State Street Corporation (1.37%) and Geode Capital Management, LLC (1.18%). Together, the top 10 institutions control 12.8% of shares outstanding. In their latest filings, 8 of the top 10 institutions increased their PLX positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of PLX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 4.05M | 4.80% | +11.9% |
| State Street Corporation | 1.16M | 1.37% | +17.6% |
| Geode Capital Management, LLC | 997.13K | 1.18% | +1.8% |
| Renaissance Technologies, LLC | 988.10K | 1.17% | -9.8% |
| Northern Trust Corporation | 922.34K | 1.09% | +4.2% |
| Dimensional Fund Advisors LP | 716.99K | 0.85% | +45.3% |
| Vanguard Portfolio Management LLC | 510.64K | 0.61% | +18.1% |
| Stratos Wealth Partners, Ltd. | 500.00K | 0.59% | 0.0% |
| Goldman Sachs Group Inc | 475.92K | 0.56% | +89.3% |
| Marshall Wace LLP | 452.76K | 0.54% | +100.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of PLX
| Fund | Shares | % Held |
|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 1.94M | 2.30% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 802.53K | 0.95% |
| iShares Trust-iShares Russell 2000 Growth ETF | 754.65K | 0.89% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 423.02K | 0.50% |
| iShares Trust-iShares Micro-Cap ETF | 250.46K | 0.30% |
| Dimensional ETF Trust-Dimensional U.S. Small Cap ETF | 215.99K | 0.26% |
| SCHWAB CAPITAL TRUST-Schwab Small-Cap Index Fund | 180.31K | 0.21% |
| Quantitative Master Series LLC-Master Small Cap Index Series | 120.80K | 0.14% |
| GOLDMAN SACHS TRUST-Goldman Sachs Absolute Return Tracker Fund | 95.64K | 0.11% |
| SPDR-EUROPE-SSgA SPDR ETFS Europe I-State Street SPDR Russell 2000 US | 91.02K | 0.11% |
Frequently asked questions
Who is the largest shareholder of Protalix BioTherapeutics (DE)?
Blackrock Inc. is the largest institutional shareholder of PLX, owning 4.80% of shares outstanding (4.05M shares) as of its latest 13F filing.
What percentage of Protalix BioTherapeutics (DE) is owned by institutions?
Institutions own about 24.0% of PLX shares and 25.0% of the public float.
How much of Protalix BioTherapeutics (DE) do insiders own?
Insiders, such as officers and directors, own about 3.72% of PLX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.